Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes physics and Newton’s laws are conspiracy.
Finding undamaged Saudi Arabian passport that fell out of an airplane in Manhattan is the truth.
So if they were bluffing how come they did not settle?
Make it like 5 to 10 questions survey and make it $50 to 100. Most doctors will respond since it is short.
We get bombarded by these type of surveys all the time. It usually pays $50 for doctor’s 20 minute time. I think this is excellent idea. This is done through 3rd party survey companies.
Great idea.
That is entirely possible approach. Now will the court accept it? They can say that generics are infringing by increasing vascepa supply beyond Marine population expectations. Will that be enough?
Doubt you can do anything based on a single slide. That is Hikma. What about Dr Ready, Apotex and Teva ? Do they have anything on them proving intent to infringe?
You eliminate one and 5 others jump in.
Have been doing cardiology since 2007. Have not seen a single patient on Edarbi.
Bidil? Nobody wants to pay for it (and I tried many times) so I use isosorbide mononitrite instead. Bidil costs $360 per month. Isosorbide costs $16.
It is hard to fool insurance companies.
It won’t work. The insurance will not honor it. That is not a strategy. Plus all of my meds are electronic. 100 percent.
The fda will not back up anything. Fda has nothing to do with what insurance will pay for. The generics will use the loophole to screw amarin. No amount of “DAW” will save us. Plus most physicians will not write “daw” anyway so it is a mute point.
It won’t work because you are impacting insurance’s bottom line. The insurance will always pay for cheaper alternative.
If that was an option, stock price would be way better than $4
Because I prescribe medication every day
Nope. Won’t work
Hmmmm. Reminds me of Jeff Epstein’s business model, who, btw, did not kill himself
Generics need to have at least 80 percent similarity in efficacy to the brand drug as per FDA. Don’t know how to prove that unless you do another CVOT with generics. In any case, I will pay for brand Vascepa.
Colchicine has always been used for the treatment of gout and for gout prophylaxis.
So this looks very similar to amarin’s case.
What new indication are you talking about?
That’s not what Markman said. They said the patent was weak.
If they thought the probability was low, they would have settled. Since they refused to settle, they thought the win is very probable. So they won.
With Europe, amarin will hit 1 billion in sales.
All these legal actions have low probability to be successful.
But certainly they can continue to hope. People do win lottery sometimes.
Generics are on top of their game. They are not stupid.
The only realistic option is issuing authorized generic, tie up the API supplies and do the volume play. But they should wait until the sales volume drops. In the meantime sell the shit out of vascepa.
We can also hope that producing generic vascepa requires significant investment and that generics cannot be profitable with low priced product.
Applying for OTC would screw generics as well but that should be down the road.
Was that your dream? What happened when you woke up?
The chance of this happening is less than 0.
What happened to the OB patents?
Is there a recourse then or this is dead? How do you correct the injustice?
They are concerned but nothing changes. No layoffs. They keep bringing me samples. She said to keep writing as many scrips as possible.
That’s what it looks like to me
No other explanation
They are waiting for generic to enter first.
Then they will see their pricing.
It will take some time for generics to ramp up their production. Maybe 1 or 2 years. In the mean time they can try to sell as many brand Vascepas as possible.
Once generics start taking over the brand vascepa they will go generic.
Yeah false hope. They cannot do anything but compete with them.
Fire reps, stop DTC and contract with apotex to make a generic.
File the lawsuit in the heavily republican states. Arkansas or Alabama.
Yup. That’s why we are screwed
Ok so why are we at $4 then?
If you put it that way I agree. How to prove infringement i am not sure.
This statement is taken out of contest. Read the whole case. It all revolves about apotex changing the dosing.
That is the apotex case.
In that case apotex changed dosing. I doubt this applies to amarin. Generics will just copy the label. Dosing is the same. Off label use permited and not ilegal.
Yes they did for marine and not for reduce it. I fail to grasp how applying for marine, which has no patents, is infringing reduce it patents?
We need a proof that they are after reduce it population. Do we have that? What is it?
I agree if you can easily prove it.
Not sure there is enough proof for that.
The only strategy left:
Tie up API supplies
Issue an autherized generic through apotex or teva because amarin needs pharmacy placement barganing power
Make it a volume play. I think this will be 500,000 weekly scripts easily
Play with the courts as a leverage. Infringement lawsuit, supreme court, etc. Probably low chance of prevailing. See what we can do with reduce it patents.
No patents so nothing to infringe
Depressing read. Not much hope amarin can do anything to reverse this.
I feel we have false hopes. This will be tough to overturn
It s says market size 752 million. I don t see anything else on page 12
5 percent is a stretch
It is 1.2 percent for trigs above 500
In the United States, the National Health and Nutrition Examination Surveys from 2007 to 2014 found that the percentages of non-statin-treated adults with triglyceride levels >150 mg/dL (1.7 mmol/L), >200 mg/dL (2.3 mmol/L), >500 mg/dL (5.7 mmol/L), and >1000 mg/dL (11.3 mmol/L) were 25, 11, 1, and <1 percent, respectively [2]. There were also racial and ethnic differences, with non-Hispanic African Americans having lower fasting TG levels than in non-Hispanic Caucasians and Mexican Americans [3].
Serum TG values >1000 mg/dL (11.3 mmol/L) occur in fewer than 1 in 5000 individuals [4].